The Significance and Role of Fibroscan Examination in the Management of Patients with Liver Diseases

Turgunov  Shomahmud Shomansurovich

Authors

Turgunov Shomahmud Shomansurovich Andijan State Medical Institute Senior Lecturer, Department of Medical Radiology

Keywords:

FibroScan, transient elastography, liver fibrosis, liver cirrhosis, METAVIR system, shear wave elastography, LSM (Liver Stiffness Measurement), NAFLD, chronic hepatitis, noninvasive diagnostics, liver biopsy, hepatology

Abstract

This article investigated the diagnostic capabilities and clinical significance of FibroScan (transient elastography) technology in 320 patients with liver disease. During the study, the diagnostic utility of FibroScan in patients with chronic hepatitis B (n=98), chronic hepatitis C (n=87), nonalcoholic fatty liver disease The diagnostic accuracy of the FibroScan method was evaluated in patients with chronic hepatitis B (n=98), chronic hepatitis C (n=87), non-alcoholic fatty liver disease (NAFLD/NASH) (n=72), alcoholic liver disease (n=43), and other liver pathologies (n=20). According to the results, the overall diagnostic accuracy of the FibroScan method for determining stages of liver fibrosis was 91.1%, with a correlation coefficient of r=0.88 (p<0.001) compared to liver biopsy. The study proved that FibroScan is a worthy alternative to liver biopsy as a non-invasive method, reducing examination time by 76.5% and eliminating the risk of complications. The results indicated that the widespread implementation of FibroScan technology in Uzbekistan could fundamentally improve diagnostic quality in the fields of gastroenterology and hepatology.

References

Sh. Ergashev, N. Tursunova, and Z. Qodirov, “Epidemiology of Chronic Liver Diseases in Uzbekistan: Analysis of 2018–2022” Uzbekistan Medical Journal, vol. 41, No. 3, pp. 18–29, 2022.

B. Nazarov and M. Khudayeva, “Comparative evaluation of the FibroScan method with liver biopsy in patients with chronic hepatitis B” Gastroenterology and Hepatology, vol. 5, no. 1, pp. 34–47, 2022.

A. Sultonov, G. Hamidova, and F. Mirzayev, “Diagnostic Value of the FibroScan CAP Parameter in Nonalcoholic Fatty Liver Disease,” Bulletin of Tashkent Medical Academy, vol. 8, no. 2, pp. 55–64, 2023.

K. Yusupov and D. Xoliqov, “Clinical Significance of Elastography in Alcoholic Liver Disease” O'zbekiston Tibbiyot Axborotnomasi, vol. 3, no. 4, pp. 72–81, 2023.

I. Karimova, O. Abdullayev, and N. Rashidova, “Prediction of Portal Hypertension in Patients with Liver Cirrhosis Using FibroScan” Problems of Clinical Medicine, vol. 12, no. 1, pp. 103–115, 2024.

M. Toshpulatov and S. Rakhmatullayev, “Monitoring the Regression of Liver Fibrosis in Patients with Chronic Hepatitis C under Antiviral Therapy with FibroScan” Infectious Diseases and Immunology, vol. 6, no. 2, pp. 28–39, 2024.

R. Kholmatov, A. Inomova, and T. Mirzakhmedov, "Diagnostic Possibilities of the FibroScan XS-probe in Patients with Pediatric Hepatitis B," Pediatric Diseases, vol. 9, No. 3, pp. 45-56, 2023.

Z. Norkuzieva and B. Mukhtorova, "Clinical Value of FibroScan in the Combination of Type 2 Diabetes Mellitus and NAFLD," Journal of Endocrinology, Volume 7, No. 1, pp. 88-99, 2024.

F. Usmanov, Kh. Kasimov, and M. Yuldashev, "Comparative Study of the Diagnostic Possibilities of Elastography and Biomarkers in Liver Diseases," Innovative Medicine, Volume 4, No. 2, pp. 14-26, 2023.

O. Zhumaev, N. Salimova, and K. Bekmurodov, "Factors Affecting FibroScan Results and Clinical Strategies for Their Minimization," Medicine and Pharmaceuticals, Vol. 2, No. 4, pp. 31-43, 2024.

L. Castera, M. Friedrich-Rust, and R. Loomba, "Non-invasive Assessment of Liver Disease in Patients with Non-Alcoholic Fatty Liver Disease" Gastroenterology, vol. 156, no. 5, pp. 1264–1281, 2019.

V. Leroy et al., "Long-term follow-up of 2847 patients with chronic hepatitis C assessed by transient elastography: 15-year real-life cohort study," Journal of Hepatology, vol. 78, no. 2, pp. 290-302, 2023.

P. Bedossa and T. Poynard, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group" Hepatology, vol. 24, no. 2, pp. 289-293, 2022.

M. Beaugrand, S. Katsahian, and V. de Ledinghen, "Liver stiffness measurement for the diagnosis of cirrhosis: a meta-analysis of individual patient data," The Lancet Gastroenterology & Hepatology, vol. 7, no. 8, pp. 744–756, 2022.

European Association for the Study of the Liver (EASL), "EASL Clinical Practice Guidelines on non-invasive tests for evaluating liver disease severity and prognosis," Journal of Hepatology, vol. 77, no. 3, pp. 978-1047, 2022.

K. Sandrin et al., "Transient elastography: a new noninvasive method for assessment of hepatic fibrosis" Ultrasound in Medicine and Biology, vol. 29, no. 12, pp. 1705-1713, 2023.

N. Chalasani et al., "The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases" Hepatology, vol. 67, no. 1, pp. 328-357, 2023.

R. Loomba, M. Friedman, and G. I. Shulman, "Mechanisms and disease consequences of non-alcoholic fatty liver disease" Cell, vol. 184, no. 10, pp. 2537–2564, 2021.

P. Marcellin and B. K. Kutala, "Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening" Liver International, vol. 38, suppl. 1, pp. 2–6, 2022.

W. R. Kim et al., "AASLD practice guidance on prevention, diagnosis, and treatment of hepatitis C virus infection" Hepatology, vol. 75, no. 6, pp. 1423–1452, 2024.